April 24th 2025
A new study shows that varenicline combined with brief remote counseling significantly improves vaping abstinence in in patients between 16 and 25 years of age.
Navigating the Increasing Complexity of Drug-Biomarker Co-Development
September 10th 2018To succeed in developing targeted medicines, companies need a biomarker strategy and the expertise to make smart decisions about clinical trial design, assays, technology platforms and collaborative partners, write Barry S. Sall and Angela X. Qu.
The Big Apple’s Fresh Start in Biotech
August 7th 2018Though challenges in space and affordability remain, New York City is emerging as a hotspot for biotech incubators, including one unique startup based in the city’s fast-growing innovation center, whose CEO, like many C-suite veterans, made the career leap from the big pharma world to forging new discoveries in medical science.
Gaining Ground with Stem Cells: Gil Van Bokkelen, Athersys
July 10th 2018While the field of regenerative medicine has grown considerably since the ’90s-in innovation and acceptance-entrenched companies such as Athersys are looking to forge new advances in the stem cell arena by transforming promising science into real-world treatments.
Pharm Exec's 2018 Pipeline Report
November 30th 2017Analysis shows that persistence is paying off for drug developers, driven by the rise of CAR-T and other gene therapy, newly discovered cancer targets, better patient identification methods-and the realization that failures have their place in shaping the pipeline of tomorrow.
The Rising Tide of Next Generation Cancer Treatments
October 2nd 2017The Ipsos Healthcare Oncology Centre of Excellence's Jackie Ilacqua & Valerie Wriede trace the evolution of cancer treatment and drill down into the latest developments currently redefining the landscape, together with those on the horizon.
Can A New Value Framework Help Ease Friction Over Orphan Drug Prices?
September 7th 2017Even on the contentious topic of orphan drug pricing, the last few months have brought hopeful signs that patients, pharmaceutical companies, health insurers, and the academic bodies that counsel them are trying to speak the same language.